A Milestone very few
Indian companies have
achieved.

24% CAGR

of Annual Revenues over
the last 29 years1

29% CAGR

of Net Profit over the
last 29 years1

30% Annualised return

to shareholders over the
last 29 years2

Over

` 48,900 Crores

Current market capitalisation3
of the Company

Over

` 5,900 Crores

Capital returned to shareholders
through dividends and buybacks
till date

Over

` 54,800 Crores

Total value created

Notes:
1. 1988 revenue and PAT numbers were for the year ending June 30, 1988. 1988 numbers are as per Indian GAAP; FY2017 numbers are reported as per IndAS.
2. Total shareholder returns compounded annually from Factset as on May 19, 2017 (assumed dividend reinvested in the stock on ex dividend date, price adjusted for stock splits and special dividend)
3. Market capitalisation as on May 19, 2017

Chairman's Message

DEAR SHAREHOLDERS

At Piramal Enterprises, creating value for all stakeholders, including our shareholders has been a defining element of our identity. Over the past 29 years, since the acquisition of Nicholas Laboratories, we have delivered annualised shareholder returns of 30%.

Our purpose at the Piramal Group
DOING WELL AND DOING GOOD

Our integrated value
creation model

The consistency of our performance is the outcome of an integrated value creation model, wherein multiple parameters and metrics work in tandem with financial and operating performance to realise sustainable growth for the long-term.

OUR BUSINESS

  • Financial Services
  • Pharma
  • Healthcare Insight & Analytics

Financial Services

PEL’s Financial Services segment offers a comprehensive suite of financial products to meet the diverse and evolving needs of its customers. The Company has created its unique positioning in the financial services space through its strong presence in the following sub-segments.

Pharma

In Pharma, PEL enjoys a strong presence in Global Pharma and India Consumer Products businesses.

Healthcare Insight & Analytics

PEL’s Healthcare Insight and Analytics business, Decision Resources Group (DRG), is a best-in-class, decision support platform in the healthcare information services space.

It provides indispensable insights to life sciences companies, and healthcare providers and payers, through a variety of high value-added data and analytics, research reports and knowledge-based services. These offerings enable customers to make informed investment, cost containment, commercial optimisation and strategic business decisions in their chosen markets.

FY2017 Highlights

GROWTH IN REVENUES

34%

TO ` 8,547 CRORES

GROWTH IN NET PROFIT

38%

TO ` 1,252 CRORES

GROWTH IN TOTAL ASSETS

56%

TO ` 48,239 CRORES

FINANCIAL SERVICES


87% Growth in Loan Book

PHARMA


20% Global Pharma EBITDA margin

HEALTHCARE INSIGHT AND ANALYTICS


250+   positions on-boarded in India offices

Key Performance Indicators

Consistently delivering strong
performance across financial,
operational and sustainable
parameters.

© Copyright 2017 - Piramal. All Rights Reserved.